This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech

Why Illumina (ILMN) Stock Is Gaining in After-Hours Trading Today

Why Illumina (ILMN) Stock Is Gaining in After-Hours Trading Today

  • Tickers in this article:
  • ILMN

Illumina (ILMN) shares are climbing in after-hours trading following its third quarter earnings beat.

10/20/14 - 05:07 PM EDT

First Detailed Look at Celgene Crohn's Disease Pill Impresses

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

10/20/14 - 10:56 AM EDT

Why Illumina (ILMN) Stock Is Gaining in After-Hours Trading Today

Why Illumina (ILMN) Stock Is Gaining in After-Hours Trading Today

  • Tickers in this article:
  • ILMN

Illumina (ILMN) shares are climbing in after-hours trading following its third quarter earnings beat.

10/20/14 - 05:07 PM EDT

First Detailed Look at Celgene Crohn's Disease Pill Impresses

First Detailed Look at Celgene Crohn's Disease Pill Impresses

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

10/20/14 - 10:56 AM EDT

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech columnist Adam Feuerstein answers readers' questions about health care.

10/17/14 - 07:05 AM EDT

Must See Charts: 4 Biotech Stocks to Watch in a Market Snapback

Must See Charts: 4 Biotech Stocks to Watch in a Market Snapback

Here are four biotechs to consider, two of which are involved in developing drugs to fight the Ebola virus.

10/17/14 - 01:50 PM EDT

FDA Approves Competing Lung Disease Drugs From Roche and Boehringer

FDA Approves Competing Lung Disease Drugs From Roche and Boehringer

  • Tickers in this article:
  • RHHBY

U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.

10/15/14 - 04:07 PM EDT

Why St. Jude Medical (STJ) Stock Is Declining Today

Why St. Jude Medical (STJ) Stock Is Declining Today

  • Tickers in this article:
  • STJ

St. Jude Medical (STJ) shares are falling after the company forecast fourth quarter revenue below analyst expectations.

10/15/14 - 12:16 PM EDT

Rally to Break Losing Streak Loses Steam; Dow Closes Lower

Wall Street started the day rallying on track to break a three-day losing streak, but at the end lost steam and closed mixed on Tuesday.

10/14/14 - 04:44 PM EDT

Why AbbVie (ABBV) Stock Is Declining in Pre-Market Trading Today

Why AbbVie (ABBV) Stock Is Declining in Pre-Market Trading Today

  • Tickers in this article:
  • ABBV

AbbVie (ABBV) shares are falling in pre-market trading after the company said that it is reconsidering it's $55 billion takeover bid for Shire Pharmaceuticals (SHPG).

10/15/14 - 09:14 AM EDT

What to Watch on Wall Street for Tuesday, October 14th 2014

On Tuesday, October 14th three major banks kick off a big week for third quarter earnings reports.

10/13/14 - 08:00 PM EDT

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price

It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.

10/14/14 - 10:53 AM EDT

Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study

Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study

  • Tickers in this article:
  • SRPT
  • RNA

Health care investors can be divided into two camps with respect to Sarepta: Those who believe eteplirsen is effective against DMD and those who don't.

10/13/14 - 12:29 PM EDT

HP Splits, Becton Buys CareFusion & LED Inventors Snag Nobel

Hewlett Packard announced Monday its plan to break into two parts while Becton Dickinson agreed to buy medical device manufacturer CareFusion

10/09/14 - 01:53 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs